- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dan Klein Outlines Policy Changes to Strengthen the Safety Net
Dan Klein, president and CEO of the Patient Access Network (PAN) Foundation, lists possible policy changes that would strengthen the safety net.
Dan Klein, president and CEO of the Patient Access Network (PAN) Foundation, lists possible policy changes that would strengthen the safety net.
Transcript
What policy changes are you looking to see that would strength the safety net?
One of the big changes we would like to see is spreading the out-of-pocket cost for Medicare patients throughout the benefit year rather than having it all hit in the beginning of the year. I think a lot of patients really could probably afford their out of pocket cost if they could spread it out. So, we’re hoping that there will be some attention towards that. We would also like to see at least one highly effective drug for each indication being placed on a non-specialty tier. So, having a copay rather than a coinsurance for at least one of the innovators specialty drugs for each indication. Then, of course, the third and one you hear more often is putting an out-of-pocket limit on the catastrophic phase in Medicare. We think that that would be helpful but it’s not gonna affect that many people. There’s only about 2% of Medicare beneficiaries who reach the catastrophic threshold.
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Prostate Cancer Studies Show Why Personalized Treatment, Trial Diversity Matter, Dorff Says
February 21st 2025Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.
Read More
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
